Opicapone dosage form and specification details and usage recommendations

Opicapone is a new long-acting peripheral COMT (catechol-O-methyltransferase) inhibitor, mainly used to assist the treatment of levodopa in patients with Parkinson's disease/Carbidopa (Levodopa/Carbidopa) program is used to extend the drug's action time, reduce the "on-off" phenomenon and improve movement fluctuations. Its mechanism of action is to inhibit peripheral COMT, thereby reducing the metabolism of levodopa throughout the body, thereby increasing the available amount of central dopamine and improving the efficacy.

The main dosage form of Opicapone is oral capsules, and common specifications are 50 mg/ capsules. The drug is designed to provide long-lasting suppression of COMT activity after a single oral administration, usually at the same time as levodopa. Compared with early short-acting COMT inhibitors, such as entacapone (Entacapone) or tolcapone (Tolcapone), Opicapone only needs to be taken once a day, which is significantly more convenient to use and puts less burden on the liver.

In terms of usage recommendations, Opicapone should be taken orally once a day at the same time, usually after taking levodopa/carbidopa. Capsules should be swallowed whole and not chewed or opened to maintain drug stability and sustained release. Patients should pay attention to whether they have adverse reactions such as mild diarrhea, constipation, dizziness or blood pressure fluctuations during medication, and communicate with their doctors so that the dosage or treatment plan can be adjusted according to symptoms.

In addition, patients' liver function, blood pressure and cardiovascular status should be assessed before using Opicapone. In particular, patients taking multiple Parkinson's disease drugs together should pay attention to drug interactions. For elderly patients or those with renal insufficiency, no special dose adjustment is generally required, but it is still recommended to closely monitor the efficacy and adverse reactions in the early stages of treatment. Through reasonable dosage form selection and standardized use, Opicapone can significantly improve motor fluctuations and improve the quality of life of patients with Parkinson's disease.

Reference link:https://www.drugs.com